Cell-Based Immunotherapy for Local Anti-CTLA4 Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy strategies using GM-CSF-expressing autologous or allogeneic cellular vaccines face limitations in efficacy due to systemic toxicity associated with the administration of anti-CTLA4 antibodies, necessitating a method to achieve therapeutic effects at lower systemic levels.
Innovation Solution
Development of cellular immunotherapy compositions that include genetically modified cells expressing GM-CSF and an anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA4) antibody, allowing for local, sustained expression at the immunization site, reducing systemic antibody concentrations while maintaining therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CTLA4 antibodies are administered systemically to enhance immune response to cancer, then therapeutic efficacy is improved, but systemic toxicity increases
Solution Approach 1:
The patent applies local quality by engineering cells to express anti-CTLA4 antibodies specifically at the immunization site rather than systemically. The genetically modified cells (e.g., tumor cells, dendritic cells, or fibroblasts) are administered locally and continuously produce the antibody at the injection site, creating a high local concentration that stimulates immune response while minimizing systemic circulation and associated toxicity.
Solution Approach 2:
The patent uses genetically modified cells as intermediaries to deliver anti-CTLA4 antibodies locally. These engineered cells act as living factories that continuously produce and secrete the antibody at the immunization site, serving as a localized delivery system that bridges the gap between systemic administration and direct local injection of the antibody.
2Reliability
If high concentrations of anti-CTLA4 antibody are administered to achieve therapeutic effect, then immune response is enhanced, but adverse events increase
Solution Approach 1:
The patent creates a localized high concentration of anti-CTLA4 antibody at the immunization site through expression by genetically modified cells. This local concentration is sufficient to enhance immune response and stimulate anti-tumor immunity without requiring high systemic concentrations that would cause adverse events such as colitis, dermatitis, or other autoimmune-like reactions.
Solution Approach 2:
The genetically modified cells provide self-service by continuously producing and secreting anti-CTLA4 antibody at the immunization site. This sustained local production maintains therapeutic antibody levels without requiring repeated systemic administrations, thereby avoiding cumulative toxicity while maintaining immune stimulation.
3Reliability
If anti-CTLA4 antibody is administered to block CTLA4 and enhance T cell activation, then anti-tumor immunity is improved, but autoimmune-like reactions occur
Solution Approach 1:
The patent localizes anti-CTLA4 antibody production to the immunization site through genetically modified cells. This creates a concentrated antibody source at the injection site that effectively blocks CTLA4-mediated inhibition of T cell activation locally, enhancing anti-tumor immunity. The localized approach limits antibody exposure to other tissues, reducing the risk of autoimmune-like reactions in organs such as the gut skin and liver.
Solution Approach 2:
The patent changes the spatial distribution parameter of anti-CTLA4 antibody from systemic to local. By engineering cells to express the antibody at the immunization site, the patent creates a steep concentration gradient with high local concentration and low systemic concentration. This parameter change allows effective CTLA4 blocking at the target site while minimizing off-target effects that cause autoimmune-like reactions.
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3B
AI summary
Cellular compositions and methods for inducing an immune response to tumor cells are described. The cellular compositions include a tumor antigen and cells that have been modified to express a cytokine and one or more of a tumor antigen, an anti-CTLA4 antibody and an additional cytokine. The cellular compositions find utility in methods for treating cancer.